Your browser doesn't support javascript.
loading
Discovery of MK-8768, a Potent and Selective mGluR2 Negative Allosteric Modulator.
Rudd, Michael T; Manley, Peter J; Hanney, Barbara; Meng, Zhaoyang; Shu, Youheng; de Leon, Pablo; Frie, Jessica L; Han, Yongxin; Wai, Jenny Miu-Chun; Yang, Zhi-Qiang; Perkins, James J; Hurzy, Danielle M; Manikowski, Jesse J; Zhu, Hong; Bungard, Christopher J; Converso, Antonella; Meissner, Robert S; Cosden, Mali L; Hayashi, Ikuo; Ma, Lei; O'Brien, Julie; Uebele, Victor N; Schachter, Joel B; Bhandari, Neetesh; Ward, Gwendolyn J; Fillgrove, Kerry L; Lu, Bing; Liang, Yuexia; Dubost, David C; Puri, Vanita; Eddins, Donnie M; Vardigan, Joshua D; Drolet, Robert E; Kern, Jonathan T; Uslaner, Jason M.
Afiliação
  • Rudd MT; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Manley PJ; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Hanney B; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Meng Z; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Shu Y; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • de Leon P; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Frie JL; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Han Y; External Discovery Chemistry, Merck & Co., Inc, Boston, Massachusetts 02115, United States.
  • Wai JM; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Yang ZQ; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Perkins JJ; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Hurzy DM; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Manikowski JJ; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Zhu H; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Bungard CJ; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Converso A; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Meissner RS; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Cosden ML; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Hayashi I; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Ma L; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • O'Brien J; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Uebele VN; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Schachter JB; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Bhandari N; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Ward GJ; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Fillgrove KL; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Lu B; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Liang Y; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Dubost DC; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Puri V; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Eddins DM; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Vardigan JD; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Drolet RE; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Kern JT; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
  • Uslaner JM; Departments of Discovery Chemistry, Neuroscience Biology Discovery, Pharmacology, Nonclinical Dug Safety, Pharmacokinetics, Discovery Pharmaceutical Sciences, and In Vivo Pharmacology, Merck & Co., Inc, West Point, Pennsylvania 19486, United States.
ACS Med Chem Lett ; 14(8): 1088-1094, 2023 Aug 10.
Article em En | MEDLINE | ID: mdl-37583812
ABSTRACT
Glutamate plays a key role in cognition and mood, and it has been shown that inhibiting ionotropic glutamate receptors disrupts cognition, while enhancing ionotropic receptor activity is pro-cognitive. One approach to elevating glutamatergic tone has been to antagonize presynaptic metabotropic glutamate receptor 2 (mGluR2). A desire for selectivity over the largely homologous mGluR3 motivated a strategy to achieve selectivity through the identification of mGluR2 negative allosteric modulators (NAMs). Extensive screening and optimization efforts led to the identification of a novel series of 4-arylquinoline-2-carboxamides. This series was optimized for mGluR2 NAM potency, clean off-target activity, and desirable physical properties, which resulted in the identification of improved C4 and C7 substituents. The initial lead compound from this series was Ames-positive in a single strain with metabolic activation, indicating that a reactive metabolite was likely responsible for the genetic toxicity. Metabolic profiling and Ames assessment across multiple analogs identified key structure-activity relationships associated with Ames positivity. Further optimization led to the Ames-negative mGluR2 negative allosteric modulator MK-8768.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Med Chem Lett Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Med Chem Lett Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos